To include your compound in the COVID-19 Resource Center, submit it here.

Flagship launches chromatin company Foghorn

Flagship Pioneering's Flagship VentureLabs launched chromatin remodeling company Foghorn Therapeutics Inc. (Cambridge, Mass.) on March 14 with a $50 million capital commitment. Foghorn's Gene Traffic Control platform identifies small molecules

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE